Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. bought 41,319 shares of Artiva Biotherapeutics stock in a transaction on Friday, July 24th. The shares were acquired at an average price of $9.99 per share, for a total transaction of $412,776.81. Following the completion of the acquisition, the director owned 17,283,802 shares of the company’s stock, valued at approximately $172,665,181.98. This represents a 0.24% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Thursday, July 23rd, Ra Capital Management, L.P. bought 59,880 shares of Artiva Biotherapeutics stock. The stock was acquired at an average cost of $9.96 per share, with a total value of $596,404.80.
- On Wednesday, July 22nd, Ra Capital Management, L.P. purchased 84,124 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $9.93 per share, with a total value of $835,351.32.
- On Tuesday, July 21st, Ra Capital Management, L.P. purchased 120,582 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $9.55 per share, for a total transaction of $1,151,558.10.
- On Friday, July 10th, Ra Capital Management, L.P. acquired 15,102 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.97 per share, for a total transaction of $135,464.94.
- On Monday, July 13th, Ra Capital Management, L.P. acquired 6,552 shares of Artiva Biotherapeutics stock. The shares were acquired at an average price of $8.94 per share, for a total transaction of $58,574.88.
- On Friday, June 26th, Ra Capital Management, L.P. acquired 1,876 shares of Artiva Biotherapeutics stock. The stock was acquired at an average price of $8.98 per share, with a total value of $16,846.48.
- On Thursday, June 25th, Ra Capital Management, L.P. bought 31,000 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.88 per share, with a total value of $275,280.00.
- On Tuesday, June 16th, Ra Capital Management, L.P. bought 124,893 shares of Artiva Biotherapeutics stock. The shares were acquired at an average cost of $8.89 per share, with a total value of $1,110,298.77.
- On Monday, June 15th, Ra Capital Management, L.P. bought 15,414 shares of Artiva Biotherapeutics stock. The shares were bought at an average price of $8.99 per share, for a total transaction of $138,571.86.
- On Friday, June 12th, Ra Capital Management, L.P. purchased 391,019 shares of Artiva Biotherapeutics stock. The stock was bought at an average cost of $8.57 per share, for a total transaction of $3,351,032.83.
Artiva Biotherapeutics Stock Up 2.0%
Artiva Biotherapeutics stock opened at $10.53 on Wednesday. The stock has a market capitalization of $260.30 million, a PE ratio of -2.97 and a beta of 2.18. Artiva Biotherapeutics, Inc. has a twelve month low of $2.22 and a twelve month high of $14.53. The company has a 50 day moving average of $8.87 and a 200-day moving average of $7.42.
Analyst Ratings Changes
ARTV has been the topic of several recent research reports. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. HC Wainwright increased their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $39.00.
Get Our Latest Analysis on Artiva Biotherapeutics
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC increased its stake in Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock valued at $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Artiva Biotherapeutics by 14,463.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Artiva Biotherapeutics during the 4th quarter worth about $341,000. Jane Street Group LLC acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $67,000. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $112,000.
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Artiva Biotherapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
